New ADHD pill tested for Year-Long safety in kids

NCT ID NCT07087327

Recruiting now Disease control Sponsor: Otsuka Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the safety of an experimental drug called EB-1020, taken once daily, in 180 children and adolescents with ADHD over 52 weeks. Researchers will monitor side effects and how well participants tolerate the medication. The trial is open to those who completed a prior study or new participants diagnosed with ADHD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

Contacts and locations

Locations

Hokkaido University Hospital
RECRUITING

Sapporo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.